Botond L Szabolcs
Overview
Explore the profile of Botond L Szabolcs including associated specialties, affiliations and a list of published articles.
Author names and details appear as published. Due to indexing inconsistencies, multiple individuals may share a name, and a single author may have variations. MedLuna displays this data as publicly available, without modification or verification
Snapshot
Snapshot
Articles
4
Citations
1
Followers
0
Related Specialties
Related Specialties
Top 10 Co-Authors
Top 10 Co-Authors
Published In
Published In
Affiliations
Affiliations
Soon will be listed here.
Recent Articles
1.
Pla I, Szabolcs B, Peter P, Ujfaludi Z, Kim Y, Horvatovich P, et al.
Int J Dermatol
. 2024 Dec;
PMID: 39722169
Background: The utilization of PD1 and CTLA4 inhibitors has revolutionized the treatment of malignant melanoma (MM). However, resistance to targeted and immune-checkpoint-based therapies still poses a significant problem. Objective: Here,...
2.
Roider E, Lakatos A, McConnell A, Wang P, Mueller A, Kawakami A, et al.
Sci Rep
. 2024 Sep;
14(1):21527.
PMID: 39277608
Microphthalmia-associated transcription factor (MITF) is a master regulator of melanocyte function, development and plays a significant role in melanoma pathogenesis. MITF genomic amplification promotes melanoma development, and it can facilitate...
3.
Pla I, Szabolcs B, Peter P, Ujfaludi Z, Kim Y, Horvatovich P, et al.
bioRxiv
. 2024 Mar;
PMID: 38545623
Highlights: (1) Proteogenomic subtype classification can define the landscape of genetic dependencies in melanoma (2) Nine proteins from molecular subtypes were identified as potential drug targets for specified MM patients...
4.
Roider E, Lakatos A, McConnell A, Wang P, Mueller A, Kawakami A, et al.
bioRxiv
. 2023 Nov;
PMID: 38014031
One Sentence Summary: MITF promote melanoma survival via increasing ROS tolerance.